Investment Thesis
Despite 13.8% revenue growth and a fortress balance sheet with minimal debt, Fulgent Genetics is severely unprofitable with -$34.6M operating losses on $71.1M revenue, indicating operating expenses are growing faster than sales and margins are deteriorating. While positive free cash flow and strong liquidity provide a financial cushion, the unsustainable -48.7% operating margin with no clear path to profitability presents substantial execution risk.
Strengths
- Fortress balance sheet with $1.0B equity, minimal debt (0.00x leverage), and $23.4M cash providing multi-year runway
- Positive revenue growth at 13.8% YoY with healthy 30.2% gross margins indicating competitive pricing power
- Positive free cash flow of $1.9M despite losses, suggesting working capital discipline and non-cash charge management
Risks
- Massive operating losses of -$34.6M (-48.7% margin) on $71.1M revenue indicates unsustainable cost structure and operating expenses growing faster than revenue
- Negative net income of -$24.8M with ROE and ROA both deeply negative, showing poor asset utilization and inability to convert revenue to profits
- Extremely thin FCF margin of 2.7% leaves minimal room for error; at current burn rate ($7.1M opex cash), company has approximately 3 years of runway despite strong balance sheet
Key Metrics to Watch
- Operating margin trajectory—must show improvement toward breakeven within 2-3 quarters to validate business model sustainability
- Operating expense ratio relative to revenue—needs to decline from current ~149% to <100% to restore profitability
- Cash burn rate and cash balance depletion timeline given widening operating losses outpacing revenue growth
Financial Metrics
Revenue
71.1M
Net Income
-24.8M
EPS (Diluted)
$-0.11
Free Cash Flow
1.9M
Total Assets
1.2B
Cash
23.4M
Profitability Ratios
Gross Margin
30.2%
Operating Margin
-48.7%
Net Margin
-34.9%
ROE
-2.4%
ROA
-2.1%
FCF Margin
2.7%
Balance Sheet & Liquidity
Current Ratio
5.31x
Quick Ratio
5.31x
Debt/Equity
0.00x
Debt/Assets
9.7%
Interest Coverage
-103.04x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T19:32:17.028170 |
Data as of: 2026-03-31 |
Powered by Claude AI